Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.
Xing WangQiang HeDingke WenLu MaChao YouPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
The results from this study suggested erenumab 140 mg might provide better efficacy than 70 mg among adult patients with migraine, without increasing TEAEs. Future elaborated RCTs with a larger number of participants are warranted to validate these discoveries.
Keyphrases